Immuron announces projects update

Immuron (IMRN) is pleased to provide shareholders with a brief update on progress with a number of projects. Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical products. Travelan Clinical Study: Topline results from the Travelan clinical study conducted by Uniformed Services University are anticipated in October 2025. IMM-529 Regulatory Milestone: Immuron plans to submit an Investigational New Drug application to the U.S. FDA for IMM-529 in mid-October 2025. ProIBS Commercial Launch: The Australian Launch of ProIBS is on track for Q4 of calendar year 2025. IMM-986 Pre-Clinical Progress: Initial pre-clinical research studies for IMM-986, targeting Vancomycin-resistant Enterococci, are anticipated to be completed by year-end 2025. Immuron is on track to exceed FY24 first quarter sales.